Host-dependent variables: The missing link to personalized medicine
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Review
PubMed
29735363
DOI
10.1016/j.ejso.2018.04.014
PII: S0748-7983(18)31020-5
Knihovny.cz E-resources
- Keywords
- Cancer, Immunobiology, Personalized medicine, Pharmacogenetics, Targeted therapy, Tumour microenvironment,
- MeSH
- Molecular Targeted Therapy methods MeSH
- Precision Medicine standards MeSH
- Clinical Trials as Topic * MeSH
- Medical Oncology methods MeSH
- Humans MeSH
- Neoplasms therapy MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Individualized medicine has the potential to tailor anticancer therapy with the best response and highest safety margin to provide better patient care. However, modern targeted therapies are still being tested through clinical trials comparing preselected patient cohorts and assessed upon behaviour of group averages. Clinically manifesting malignant disease requires identification of host- and tumour-dependent variables such as biological characteristics of the tumour and its microenvironment including immune response features, and overall capacity of the host to receive, tolerate and efficiently utilize treatment. Contemporary medical oncology including clinical trial design need to refocus from assessing group averages to individuality taking into consideration time dependent host-associated characteristics and reinventing outliers to be appreciated as naturally occurring variables collectively determining the ultimate outcome of malignant disease.
References provided by Crossref.org
